[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336796-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-336796-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","inactivation-of-hipk2-attenuates-krasg12d-activity-and-prevents-pancreatic-tumorigenesis","Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis","","Pancreatic ductal adenocarcinoma (PDAC) commonly features KRAS mutations alongside an excessive stromal response, the desmoplastic reaction. Prior work indicated that Homeodomain-Interacting Protein Kinase 2 (HIPK2) cooperates with KRAS to sustain ERK1/2 phosphorylation in colorectal cancer. This study tests whether HIPK2 contributes to oncogenic KRAS-driven tumorigenesis in vivo during pancreatic cancer onset. Using KRASG12D-dependent preinvasive PDAC models, genetic or pharmacologic HIPK2 inhibition reduced ERK phosphorylation, slowed ADM, decreased PanIN number and grade, and altered the tumor microenvironment toward a matrix-rich, cell-poor phenotype.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/inactivation-of-hipk2-attenuates-krasg12d-activity-and-prevents-pancreatic-tumorigenesis/336796/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/inactivation-of-hipk2-attenuates-krasg12d-activity-and-prevents-pancreatic-tumorigenesis/336796.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What problem does the study address in pancreatic cancer?","Question",{"text":62,"@type":63},"PDAC frequently shows KRAS mutations and an excessive stromal response termed desmoplastic reaction. The study focuses on whether HIPK2 helps KRAS drive tumorigenesis during pancreatic cancer onset.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How was HIPK2 inhibited in the KRASG12D mouse model?",{"text":67,"@type":63},"HIPK2 was inhibited either genetically by knockout in pancreatic epithelial cells (KCH−/−) or pharmacologically using the small molecule 5-IodoTubercidin (5-ITu).",{"name":69,"@type":60,"acceptedAnswer":70},"What were the main effects of HIPK2 inhibition on tumor precursors and signaling?",{"text":71,"@type":63},"In Hipk2-KO mice, ERK phosphorylation decreased, acinar-to-ductal metaplasia (ADM) appeared more slowly, and PanIN number and pathologic grade were reduced. The phenotype also showed increased collagen fibers and fewer αSMA+ and pSTAT3+ desmoplastic cells.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},336796,1791106762,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Sozzi et al. J Exp Clin Cancer Res (2024) 43:265 [https://doi.org/10.1186/s13046-024-03189-3](https://doi.org/10.1186/s13046-024-03189-3)  \nJournal of Experimental & Clinical Cancer Research  \n RESEARCH Open Access  \nInactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis  \nSilvia Sozzi1,2†, Isabella Manni3†, Cristiana Ercolani4, Maria Grazia Diodoro4, Armando Bartolazzi5, Francesco Spallotta6, Giulia Piaggio3, Laura Monteonofrio 1, Silvia Soddu1†, Cinzia Rinaldo 1,7*† and Davide Valente1,7*†  \nAbstract  \nBackground Pancreatic ductal adenocarcinoma (PDAC) features KRAS mutations in approximately 90% of human cases and excessive stromal response, termed desmoplastic reaction. Oncogenic KRAS drives pancreatic carcinogenesis by acting on both epithelial cells and tumor microenvironment (TME) . We have previously shown that Homeodomain-Interacting Protein Kinase 2 (HIPK2) cooperates with KRAS in sustaining ERK1/2 phosphorylation in human colorectal cancers. Here, we investigated whether HIPK2 contributes to oncogenic KRAS-driven tumorigenesis in vivo, in the onset of pancreatic cancer.  \nMethods We employed an extensively characterized model of KRASG12D-dependent preinvasive PDAC, the Pdx1-Cre;LSL-KRasG12D/+ (KC) mice. In these mice, HIPK2 was inhibited by genetic knockout in the pancreatic epithelial cells (KCH−/− ) or by pharmacologic inactivation with the small molecule 5-IodoTubercidin (5-ITu) . The development of preneoplastic acinar-to-ductal metaplasia (ADM), intraepithelial neoplasia (PanIN), and their associated desmoplastic reaction were analyzed.  \nResults In Hipk2-KO mice (KCH−/−), ERK phosphorylation was lowered, the appearance of ADM was slowed down, and both the number and pathologic grade of PanIN were reduced compared to Hipk2-WT KC mice. The pancreatic lesion phenotype in KCH−/− mice was characterized by abundant collagen fibers and reduced number of αSMA+ and pSTAT3+ desmoplastic cells. These features were reminiscent of the recently described human “deserted” sub-TME, poor in cells, rich in matrix, and associated with tumor differentiation. In contrast, the desmoplastic reaction of KC mice resembled the “reactive” sub-TME, rich in stromal cells and associated with tumor progression. These observations were confirmed by the pharmacologic inhibition of HIPK2 in KC mice.  \nConclusion This study demonstrates that HIPK2 inhibition weakens oncogenic KRAS activity and pancreatic tumorigenesis providing a rationale for testing HIPK2 inhibitors to mitigate the incidence of PDAC development in high-risk individuals.  \nKeywords HIPK2, KRAS, Pancreatic tumorigenesis  \n\n| †Silvia Sozzi and Isabella Manni shared co-first authorship. |\n| --- |\n| †Silvia Soddu, Cinzia Rinaldo and Davide Valente jointly supervised this work. |\n\n*Correspondence:  \nCinzia Rinaldo  \n[cinzia. rinaldo@uniroma1.it](cinzia. rinaldo@uniroma1.it)  \nDavide Valente  \n[davide.valente@ifo.it](davide.valente@ifo.it); [davide.valente@cnr.it](davide.valente@cnr.it)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licen","cbCaiekyFBmDK8aY","https://ap.wps.com/l/cbCaiekyFBmDK8aY","pdf",3560612,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Graphical Abstract\n# Background","[{\"question\":\"What problem does the study address in pancreatic cancer?\",\"answer\":\"PDAC frequently shows KRAS mutations and an excessive stromal response termed desmoplastic reaction. The study focuses on whether HIPK2 helps KRAS drive tumorigenesis during pancreatic cancer onset.\"},{\"question\":\"How was HIPK2 inhibited in the KRASG12D mouse model?\",\"answer\":\"HIPK2 was inhibited either genetically by knockout in pancreatic epithelial cells (KCH−/−) or pharmacologically using the small molecule 5-IodoTubercidin (5-ITu).\"},{\"question\":\"What were the main effects of HIPK2 inhibition on tumor precursors and signaling?\",\"answer\":\"In Hipk2-KO mice, ERK phosphorylation decreased, acinar-to-ductal metaplasia (ADM) appeared more slowly, and PanIN number and pathologic grade were reduced. The phenotype also showed increased collagen fibers and fewer αSMA+ and pSTAT3+ desmoplastic cells.\"}]","Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis | PDF",1790016655,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/662b89fd8f1e5041e044079aa28fdf01.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b69c2cf21efcfaf4312cf1dd1fd7662f.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86caa5513d1b29737930f238a3523bef.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f63eda6c92fdedafc489b371db0e945.webp",980,1301]